Diadema Partners’s Apogee Therapeutics APGE Stock Holding History

Diadema Partners’s Portfolio APGE Stock Details APGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-64,250	Closed	-$4.05M	–	152
2025 Q3	$2.55M	Buy	64,250 +53,678	+508%	+$2.05M	0.65%	53
2025 Q2	$459K	Sell	10,572 -29,428	-74%	-$1.12M	0.14%	79
2025 Q1	$1.49M	Sell	40,000 -10,620	-21%	-$411K	0.39%	53
2024 Q4	$2.29M	Buy	+50,620	New	+$2.58M	0.98%	32

Other funds holding APGE

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

Diadema Partners's APGE Position: Q4 2025 in Review

Diadema Partners sold out of Apogee Therapeutics (APGE) in Q4 2025, closing a stake of 64,250 shares — an estimated $4.05M sold.

Diadema Partners first reported a position in APGE in Q4 2024 and held it in 4 quarters. The position peaked at $2.55M in Q3 2025. 206 funds tracked by Wall St. Rank hold APGE as of Q4 2025.

Diadema Partners reported no remaining Apogee Therapeutics position as of Q4 2025 after selling out during the quarter.
Diadema Partners sold 64,250 Apogee Therapeutics shares in Q4 2025, an estimated $4.05M.
Diadema Partners first reported a position in Apogee Therapeutics in Q4 2024 and held it in 4 quarters.
Diadema Partners's Apogee Therapeutics position peaked at $2.55M in Q3 2025.
206 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q4 2025.

Based on Diadema Partners's 13F filing for Q4 2025, filed 17 Feb 2026.